United Therapeutics' second quarter saw sales increase year-on-year, but performance missed Wall Street’s expectations on both revenue and non-GAAP earnings per share, prompting a significant negative market reaction. Management attributed the double-digit revenue growth to continued strength in the Tyvaso franchise, particularly Tyvaso DPI, which achieved record patient shipments and robust new starts. CEO Martine Rothblatt highlighted operational efficiency and emphasized the company’s broad commercial portfolio, but acknowledged heightened competitive pressures, especially from new treprostinil products entering the market. President Michael Benkowitz noted, “We finished Q2 really strong in terms of shipments and orders in June. July, based on what we're seeing so far, looks really good.”

Is now the time to buy UTHR? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From United Therapeutics’s Q2 Earnings Call

• Olivia Simone Brayer (Cantor Fitzgerald): Asked about Yutrepia’s early uptake and its impact on Tyvaso DPI. President Michael Benkowitz responded that, while some physicians are trying the new product, Tyvaso DPI’s shipment and order trends remain strong, and the company is confident in its long-term competitive position.
• Joseph John-Charles Thome (TD Cowen): Inquired about efforts to standardize FVC (forced vital capacity) measurements in the TETON trial, given historical variability. Dr. Leigh Peterson explained that central reading and extensive site training were implemented to reduce measurement variability and improve the reliability of study results.
• Jessica Macomber Fye (JPMorgan): Sought clarification on how improvements observed in pulmonary hypertension subgroups could translate to IPF patients in TETON. Dr. Peterson highlighted treprostinil’s multiple mechanisms of action, stating that its antifibrotic effects could extend efficacy beyond patients with pulmonary hypertension.
• Roger Song (Jefferies): Questioned the clinical significance of FVC results and the proportion of TETON patients with concurrent pulmonary hypertension. Dr. C.Q. Deng clarified that TETON was designed to enroll a typical IPF population, not specifically those with pulmonary hypertension, to focus on antifibrotic effects.
• Andreas Argyrides (Oppenheimer): Requested more details on ralinepag’s once-daily dosing potential and TETON’s statistical powering. Dr. Peterson confirmed the ADVANCE OUTCOMES study is powered to detect meaningful differences and remains on track for event-driven readout by year-end.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely watch (1) the September TETON 2 data readout for signs of efficacy in idiopathic pulmonary fibrosis and its implications for Tyvaso’s expansion, (2) market share trends for Tyvaso DPI as new PAH competitors enter the market, and (3) progress on next-generation product launches and broader pipeline milestones such as ralinepag and organ transplantation studies. Execution on these fronts will be central to United Therapeutics’ growth narrative.

United Therapeutics currently trades at $302.78, up from $297.16 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.